{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:25:28Z","timestamp":1782854728841,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FRN-167269"],"award-info":[{"award-number":["FRN-167269"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["CRC-2020-00067"],"award-info":[{"award-number":["CRC-2020-00067"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>High expression of the glycosyltransferase UGT2B17 represents an independent adverse prognostic marker in chronic lymphocytic leukemia (CLL). It also constitutes a predictive marker for therapeutic response and a drug resistance mechanism. The key determinants driving expression of the <jats:italic>UGT2B17<\/jats:italic> gene in normal and leukemic B-cells remain undefined. The <jats:italic>UGT2B17<\/jats:italic> transcriptome is complex and is comprised of at least 10 alternative transcripts, identified by previous RNA-sequencing of liver and intestine. We hypothesized that the transcriptional program regulating <jats:italic>UGT2B17<\/jats:italic> in B-lymphocytes is distinct from the canonical expression previously characterized in the liver.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>RNA-sequencing and genomics data revealed a specific genomic landscape at the <jats:italic>UGT2B17<\/jats:italic> locus in normal and leukemic B-cells. RNA-sequencing and quantitative PCR data indicated that the UGT2B17 enzyme is solely encoded by alternative transcripts expressed in CLL patient cells and not by the canonical transcript widely expressed in the liver and intestine. Chromatin accessible regions (ATAC-Seq) in CLL cells mapped with alternative promoters and non-coding exons, which may be derived from endogenous retrotransposon elements. By luciferase reporter assays, we identified key cis-regulatory STAT3, RELA and interferon regulatory factor (IRF) binding sequences driving the expression of UGT2B17 in lymphoblastoid and leukemic B-cells. Electrophoretic mobility shift assays and pharmacological inhibition demonstrated key roles for the CLL prosurvival transcription factors STAT3 and NF-\u03baB in the leukemic expression of UGT2B17.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>UGT2B17 expression in B-CLL is driven by key regulators of CLL progression. Our data suggest that a NF-\u03baB\/STAT3\/IRF\/UGT2B17 axis may represent a novel B-cell pathway promoting disease progression and drug resistance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12143-7","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T08:01:55Z","timestamp":1712044915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-canonical transcriptional regulation of the poor prognostic factor UGT2B17 in chronic lymphocytic leukemic and normal B cells"],"prefix":"10.1186","volume":"24","author":[{"given":"Mich\u00e8le","family":"Rouleau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyne","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Allain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"McCabe-Leroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Nguyen Van Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Uchil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Joly-Beauparlant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Droit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Guillemette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"12143_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41416-019-0722-0","volume":"122","author":"EP Allain","year":"2020","unstructured":"Allain EP, Rouleau M, Levesque E, Guillemette C. Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression. Br J Cancer. 2020;122:1277\u201387.","journal-title":"Br J Cancer"},{"key":"12143_CR2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41416-020-0887-6","volume":"123","author":"EP Allain","year":"2020","unstructured":"Allain EP, Rouleau M, Vanura K, Tremblay S, Vaillancourt J, Bat V, et al. UGT2B17 modifies drug response in chronic lymphocytic leukaemia. Br J Cancer. 2020;123:240\u201351.","journal-title":"Br J Cancer"},{"key":"12143_CR3","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2012-08-447359","volume":"121","author":"M Gruber","year":"2013","unstructured":"Gruber M, Bellemare J, Hoermann G, Gleiss A, Porpaczy E, Bilban M, et al. Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. Blood. 2013;121:1175\u201383.","journal-title":"Blood"},{"key":"12143_CR4","doi-asserted-by":"publisher","first-page":"e01154","DOI":"10.1002\/prp2.1154","volume":"11","author":"L Zhou","year":"2023","unstructured":"Zhou L, Montalvo AD, Collins JM, Wang D. Quantitative analysis of the UDP-glucuronosyltransferase transcriptome in human tissues. Pharmacol Res Perspect. 2023;11:e01154.","journal-title":"Pharmacol Res Perspect"},{"key":"12143_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00606","author":"EP Allain","year":"2019","unstructured":"Allain EP, Rouleau M, Le T, Vanura K, Villeneuve L, Caron P, et al. Inactivation of prostaglandin E2 as a mechanism for UGT2B17-mediated adverse effects in chronic lymphocytic leukemia. Front Oncol. 2019. https:\/\/doi.org\/10.3389\/fonc.2019.00606.","journal-title":"Front Oncol"},{"key":"12143_CR6","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.3324\/haematol.2015.136440","volume":"101","author":"S Bhoi","year":"2016","unstructured":"Bhoi S, Baliakas P, Cortese D, Mattsson M, Engvall M, Smedby KE, et al. UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia? Haematologica. 2016;101:e63\u20135.","journal-title":"Haematologica"},{"key":"12143_CR7","doi-asserted-by":"crossref","unstructured":"Nguyen Van Long F, Valcourt-Gendron D, Caron P, Rouleau M, Villeneuve L, Simonyan D et al. Untargeted metabolomics identifies metabolic dysregulation of sphingolipids associated with aggressive chronic lymphocytic leukemia and poor survival. Clin Transl Med. 2023;13:e1442.","DOI":"10.1002\/ctm2.1442"},{"key":"12143_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/tpj.2015.20","volume":"16","author":"A Tourancheau","year":"2016","unstructured":"Tourancheau A, Margaillan G, Rouleau M, Gilbert I, Villeneuve L, Levesque E, et al. Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA sequencing. Pharmacogenomics J. 2016;16:60\u201370.","journal-title":"Pharmacogenomics J"},{"key":"12143_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/tpj.2017.5","volume":"18","author":"A Tourancheau","year":"2018","unstructured":"Tourancheau A, Rouleau M, Guauque-Olarte S, Villeneuve L, Gilbert I, Droit A, et al. Quantitative profiling of the UGT transcriptome in human drug-metabolizing tissues. Pharmacogenomics J. 2018;18:251\u201361.","journal-title":"Pharmacogenomics J"},{"key":"12143_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1124\/dmd.119.086330","volume":"47","author":"JP Emond","year":"2019","unstructured":"Emond JP, Labriet A, Desjardins S, Rouleau M, Villeneuve L, Hovington H, et al. Factors affecting interindividual variability of hepatic UGT2B17 protein expression examined using a Novel specific monoclonal antibody. Drug Metab Dispos. 2019;47:444\u201352.","journal-title":"Drug Metab Dispos"},{"key":"12143_CR11","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1124\/dmd.110.035436","volume":"38","author":"DG Hu","year":"2010","unstructured":"Hu DG, Mackenzie PI. Forkhead box protein A1 regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells. Drug Metab Dispos. 2010;38:2105\u20139.","journal-title":"Drug Metab Dispos"},{"key":"12143_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3109\/03602532.2014.973037","volume":"46","author":"DG Hu","year":"2014","unstructured":"Hu DG, Meech R, McKinnon RA, Mackenzie PI. Transcriptional regulation of human UDP-glucuronosyltransferase genes. Drug Metab Rev. 2014;46:421\u201358.","journal-title":"Drug Metab Rev"},{"key":"12143_CR13","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/s41416-020-0749-2","volume":"122","author":"E Levesque","year":"2020","unstructured":"Levesque E, Labriet A, Hovington H, Allain EP, Melo-Garcia L, Rouleau M, et al. Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression. Br J Cancer. 2020;122:1068\u201376.","journal-title":"Br J Cancer"},{"key":"12143_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jsbmb.2015.09.021","volume":"155","author":"G Margaillan","year":"2016","unstructured":"Margaillan G, Levesque E, Guillemette C. Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer. J Steroid Biochem Mol Biol. 2016;155:85\u201393.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"12143_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1124\/jpet.115.226118","volume":"354","author":"DD Wijayakumara","year":"2015","unstructured":"Wijayakumara DD, Hu DG, Meech R, McKinnon RA, Mackenzie PI. Regulation of human UGT2B15 and UGT2B17 by miR-376c in prostate Cancer cell lines. J Pharmacol Exp Ther. 2015;354:417\u201325.","journal-title":"J Pharmacol Exp Ther"},{"key":"12143_CR16","doi-asserted-by":"publisher","first-page":"11938","DOI":"10.1038\/ncomms11938","volume":"7","author":"AF Rendeiro","year":"2016","unstructured":"Rendeiro AF, Schmidl C, Strefford JC, Walewska R, Davis Z, Farlik M, et al. Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks. Nat Commun. 2016;7:11938.","journal-title":"Nat Commun"},{"key":"12143_CR17","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1101\/gr.229102","volume":"12","author":"WJ Kent","year":"2002","unstructured":"Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res. 2002;12:996\u20131006.","journal-title":"Genome Res"},{"key":"12143_CR18","doi-asserted-by":"crossref","unstructured":"Wagner A, Rouleau M, Villeneuve L, Le T, Peltier C, Allain EP et al. A non-canonical role for the glycosyltransferase enzyme UGT2B17 as a Novel Constituent of the B cell receptor signalosome. Cells. 2023;12.","DOI":"10.3390\/cells12091295"},{"key":"12143_CR19","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.ccell.2018.11.001","volume":"34","author":"CJ Ott","year":"2018","unstructured":"Ott CJ, Federation AJ, Schwartz LS, Kasar S, Klitgaard JL, Lenci R, et al. Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell. 2018;34:982\u201395. e7.","journal-title":"Cancer Cell"},{"key":"12143_CR20","doi-asserted-by":"publisher","first-page":"e55146","DOI":"10.15252\/embr.202255146","volume":"23","author":"B Dehingia","year":"2022","unstructured":"Dehingia B, Milewska M, Janowski M, Pekowska A. CTCF shapes chromatin structure and gene expression in health and disease. EMBO Rep. 2022;23:e55146.","journal-title":"EMBO Rep"},{"key":"12143_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41594-020-00539-5","volume":"28","author":"N Kubo","year":"2021","unstructured":"Kubo N, Ishii H, Xiong X, Bianco S, Meitinger F, Hu R, et al. Promoter-proximal CTCF binding promotes distal enhancer-dependent gene activation. Nat Struct Mol Biol. 2021;28:152\u201361.","journal-title":"Nat Struct Mol Biol"},{"key":"12143_CR22","doi-asserted-by":"crossref","first-page":"D87","DOI":"10.1093\/nar\/gkaa516","volume":"48","author":"O Fornes","year":"2020","unstructured":"Fornes O, Castro-Mondragon JA, Khan A, van der Lee R, Zhang X, Richmond PA, et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2020;48:D87\u201392.","journal-title":"Nucleic Acids Res"},{"key":"12143_CR23","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1101\/gr.240663.118","volume":"29","author":"L Garcia-Alonso","year":"2019","unstructured":"Garcia-Alonso L, Holland CH, Ibrahim MM, Turei D, Saez-Rodriguez J. Benchmark and integration of resources for the estimation of human transcription factor activities. Genome Res. 2019;29:1363\u201375.","journal-title":"Genome Res"},{"key":"12143_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1097\/00008571-200012000-00006","volume":"10","author":"PA Gregory","year":"2000","unstructured":"Gregory PA, Hansen AJ, Mackenzie PI. Tissue specific differences in the regulation of the UDP glucuronosyltransferase 2B17 gene promoter. Pharmacogenetics. 2000;10:809\u201320.","journal-title":"Pharmacogenetics"},{"key":"12143_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1124\/mol.62.1.154","volume":"62","author":"PA Gregory","year":"2002","unstructured":"Gregory PA, Mackenzie PI. The homeodomain Pbx2-Prep1 complex modulates hepatocyte nuclear factor 1alpha-mediated activation of the UDP-glucuronosyltransferase 2B17 gene. Mol Pharmacol. 2002;62:154\u201361.","journal-title":"Mol Pharmacol"},{"key":"12143_CR26","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/ng.490","volume":"41","author":"SA McCarroll","year":"2009","unstructured":"McCarroll SA, Bradner JE, Turpeinen H, Volin L, Martin PJ, Chilewski SD, et al. Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet. 2009;41:1341\u20134.","journal-title":"Nat Genet"},{"key":"12143_CR27","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1084\/jem.20030044","volume":"197","author":"M Murata","year":"2003","unstructured":"Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med. 2003;197:1279\u201389.","journal-title":"J Exp Med"},{"key":"12143_CR28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/ejh.13921","volume":"110","author":"Y Chen","year":"2023","unstructured":"Chen Y, Shao X, Yang H, Ren L, Cui Y, Zhang W, et al. Interferon gamma regulates a complex pro-survival signal network in chronic lymphocytic leukemia. Eur J Haematol. 2023;110:435\u201343.","journal-title":"Eur J Haematol"},{"key":"12143_CR29","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1158\/1535-7163.MCT-10-0550","volume":"9","author":"G Ishdorj","year":"2010","unstructured":"Ishdorj G, Johnston JB, Gibson SB. Inhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human B-leukemia cells to apoptosis. Mol Cancer Ther. 2010;9:3302\u201314.","journal-title":"Mol Cancer Ther"},{"key":"12143_CR30","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1182\/blood-2009-10-230060","volume":"115","author":"I Hazan-Halevy","year":"2010","unstructured":"Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, Chen X, et al. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood. 2010;115:2852\u201363.","journal-title":"Blood"},{"key":"12143_CR31","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1182\/blood.2019001366","volume":"134","author":"Y Chen","year":"2019","unstructured":"Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, et al. Cirmtuzumab blocks Wnt5a\/ROR1 stimulation of NF-kappaB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019;134:1084\u201394.","journal-title":"Blood"},{"key":"12143_CR32","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/1541-7786.MCR-14-0412","volume":"13","author":"U Rozovski","year":"2015","unstructured":"Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, et al. Aberrant LPL expression, driven by STAT3, mediates free fatty acid metabolism in CLL cells. Mol Cancer Res. 2015;13:944\u201353.","journal-title":"Mol Cancer Res"},{"key":"12143_CR33","doi-asserted-by":"publisher","first-page":"2126880","DOI":"10.18632\/oncotarget.25066","volume":"9","author":"U Rozovski","year":"2018","unstructured":"Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, et al. STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget. 2018;9:2126880.","journal-title":"Oncotarget"},{"key":"12143_CR34","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.4049\/jimmunol.1900389","volume":"203","author":"U Rozovski","year":"2019","unstructured":"Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, et al. STAT3-Induced Wnt5a provides chronic lymphocytic leukemia cells with survival advantage. J Immunol. 2019;203:3078\u201385.","journal-title":"J Immunol"},{"key":"12143_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.18632\/oncotarget.27884","volume":"12","author":"U Rozovski","year":"2021","unstructured":"Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, et al. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget. 2021;12:401\u201311.","journal-title":"Oncotarget"},{"key":"12143_CR36","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.4049\/jimmunol.2101105","volume":"208","author":"U Rozovski","year":"2022","unstructured":"Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, et al. STAT3 activates the Pentraxin 3 gene in chronic lymphocytic leukemia cells. J Immunol. 2022;208:2847\u201355.","journal-title":"J Immunol"},{"key":"12143_CR37","doi-asserted-by":"publisher","first-page":"32031","DOI":"10.18632\/oncotarget.8672","volume":"7","author":"FT Liu","year":"2016","unstructured":"Liu FT, Jia L, Wang P, Wang H, Farren TW, Agrawal SG. STAT3 and NF-kappaB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia. Oncotarget. 2016;7:32031\u201345.","journal-title":"Oncotarget"},{"key":"12143_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrc.2016.8","volume":"16","author":"G Fabbri","year":"2016","unstructured":"Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer. 2016;16:145\u201362.","journal-title":"Nat Rev Cancer"},{"key":"12143_CR39","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1002\/ijc.30892","volume":"141","author":"U Rozovski","year":"2017","unstructured":"Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, et al. Activation of the B-cell receptor successively activates NF-kappaB and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer. 2017;141:2076\u201381.","journal-title":"Int J Cancer"},{"key":"12143_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/10428194.2022.2131408","volume":"64","author":"X Shao","year":"2023","unstructured":"Shao X, Meng X, Yang H, Wang X, Qin L, Shen G, et al. IFN-gamma enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway. Leuk Lymphoma. 2023;64:71\u20138.","journal-title":"Leuk Lymphoma"},{"key":"12143_CR41","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3389\/fimmu.2019.01176","volume":"10","author":"A Antonczyk","year":"2019","unstructured":"Antonczyk A, Krist B, Sajek M, Michalska A, Piaszyk-Borychowska A, Plens-Galaska M, et al. Direct inhibition of IRF-Dependent Transcriptional Regulatory mechanisms Associated with Disease. Front Immunol. 2019;10:1176.","journal-title":"Front Immunol"},{"key":"12143_CR42","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/s41375-021-01178-5","volume":"35","author":"R Maffei","year":"2021","unstructured":"Maffei R, Fiorcari S, Benatti S, Atene CG, Martinelli S, Zucchini P, et al. IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK. Leukemia. 2021;35:1330\u201343.","journal-title":"Leukemia"},{"key":"12143_CR43","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41416-020-1005-5","volume":"123","author":"SI Papamichos","year":"2020","unstructured":"Papamichos SI, Jungbauer C. Comment on: UGT2B17 modifies drug response in chronic lymphocytic leukaemia. Br J Cancer. 2020;123:1345\u20136.","journal-title":"Br J Cancer"},{"key":"12143_CR44","first-page":"4978","volume":"130","author":"SI Papamichos","year":"2017","unstructured":"Papamichos SI, Lamprianidou E, Kordella C, Spanoudakis E, Papoutselis MK, Kotsianidis I. Endogenous retrovirus derepression drives ectopic UGT2B17 overexpression in multiple myeloma cells: molecular sequelae and pathophysiological implications. Blood. 2017;130:4978.","journal-title":"Blood"},{"key":"12143_CR45","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1038\/s41416-020-1006-4","volume":"123","author":"C Guillemette","year":"2020","unstructured":"Guillemette C, Rouleau M, Vanura K, Levesque E. Reply to comment on UGT2B17 modifies drug response in chronic lymphocytic leukaemia. Br J Cancer. 2020;123:1347\u20138.","journal-title":"Br J Cancer"},{"key":"12143_CR46","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1182\/blood-2005-02-0597","volume":"106","author":"Y Renaudineau","year":"2005","unstructured":"Renaudineau Y, Hillion S, Saraux A, Mageed RA, Youinou P. An alternative exon 1 of the CD5 gene regulates CD5 expression in human B lymphocytes. Blood. 2005;106:2781\u20139.","journal-title":"Blood"},{"key":"12143_CR47","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/35057062","volume":"409","author":"ES Lander","year":"2001","unstructured":"Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860\u2013921.","journal-title":"Nature"},{"key":"12143_CR48","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.4049\/jimmunol.1302972","volume":"192","author":"G Kassiotis","year":"2014","unstructured":"Kassiotis G. Endogenous retroviruses and the development of cancer. J Immunol. 2014;192:1343\u20139.","journal-title":"J Immunol"},{"key":"12143_CR49","doi-asserted-by":"crossref","unstructured":"Stricker E, Peckham-Gregory EC, Scheurer ME. HERVs and Cancer-A Comprehensive Review of the relationship of human endogenous retroviruses and human cancers. Biomedicines. 2023;11.","DOI":"10.3390\/biomedicines11030936"},{"key":"12143_CR50","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1101\/gr.152132.112","volume":"24","author":"PG Ferreira","year":"2014","unstructured":"Ferreira PG, Jares P, Rico D, Gomez-Lopez G, Martinez-Trillos A, Villamor N, et al. Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res. 2014;24:212\u201326.","journal-title":"Genome Res"},{"key":"12143_CR51","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1101\/gr.248922.119","volume":"29","author":"J Attig","year":"2019","unstructured":"Attig J, Young GR, Hosie L, Perkins D, Encheva-Yokoya V, Stoye JP, et al. LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly. Genome Res. 2019;29:1578\u201390.","journal-title":"Genome Res"},{"key":"12143_CR52","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1038\/onc.2015.308","volume":"35","author":"A Babaian","year":"2016","unstructured":"Babaian A, Romanish MT, Gagnier L, Kuo LY, Karimi MM, Steidl C, et al. Onco-Exaptation of an endogenous retroviral LTR drives IRF5 expression in Hodgkin lymphoma. Oncogene. 2016;35:2542\u20136.","journal-title":"Oncogene"},{"key":"12143_CR53","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41588-019-0373-3","volume":"51","author":"HS Jang","year":"2019","unstructured":"Jang HS, Shah NM, Du AY, Dailey ZZ, Pehrsson EC, Godoy PM, et al. Transposable elements drive widespread expression of oncogenes in human cancers. Nat Genet. 2019;51:611\u20137.","journal-title":"Nat Genet"},{"key":"12143_CR54","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nri.2016.27","volume":"16","author":"G Kassiotis","year":"2016","unstructured":"Kassiotis G, Stoye JP. Immune responses to endogenous retroelements: taking the bad with the good. Nat Rev Immunol. 2016;16:207\u201319.","journal-title":"Nat Rev Immunol"},{"key":"12143_CR55","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41588-023-01349-3","volume":"55","author":"NM Shah","year":"2023","unstructured":"Shah NM, Jang HJ, Liang Y, Maeng JH, Tzeng SC, Wu A, et al. Pan-cancer analysis identifies tumor-specific antigens derived from transposable elements. Nat Genet. 2023;55:631\u20139.","journal-title":"Nat Genet"},{"key":"12143_CR56","doi-asserted-by":"crossref","unstructured":"Ku Y, Park JH, Cho R, Lee Y, Park HM, Kim M et al. Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs. Proc Natl Acad Sci U S A. 2021;118.","DOI":"10.1073\/pnas.2016289118"},{"key":"12143_CR57","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.steroids.2015.07.009","volume":"104","author":"P Caron","year":"2015","unstructured":"Caron P, Turcotte V, Guillemette C. A chromatography\/tandem mass spectrometry method for the simultaneous profiling of ten endogenous steroids, including progesterone, adrenal precursors, androgens and estrogens, using low serum volume. Steroids. 2015;104:16\u201324.","journal-title":"Steroids"},{"key":"12143_CR58","first-page":"367","volume":"37","author":"J Zhang","year":"2019","unstructured":"Zhang J, Bajari R, Andric D, Gerthoffert F, Lepsa A, Nahal-Bose H, et al. Int Cancer Genome Consortium Data Portal Nat Biotechnol. 2019;37:367\u20139.","journal-title":"Int Cancer Genome Consortium Data Portal Nat Biotechnol"},{"key":"12143_CR59","doi-asserted-by":"publisher","first-page":"8218","DOI":"10.1038\/s41598-019-44491-x","volume":"9","author":"H Quentmeier","year":"2019","unstructured":"Quentmeier H, Pommerenke C, Dirks WG, Eberth S, Koeppel M, MacLeod RAF, et al. The LL-100 panel: 100 cell lines for blood cancer studies. Sci Rep. 2019;9:8218.","journal-title":"Sci Rep"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12143-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12143-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12143-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T09:08:18Z","timestamp":1712048898000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12143-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12143"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12143-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"assertion":[{"value":"22 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the ethical research committee of the CHU de Qu\u00e9bec (2015-1205). Part of this study used publicly available data generated with human specimens that received informed consent from all participants and prior approval from the appropriate institutional review boards as reported in the original reports. No further informed permission was needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"410"}}